Vista Medical Services, Inc. - Medicare Mental Health Clinic in Bala Cynwyd, PA

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

News Archive

Obesity increases viral shedding duration in adults with influenza A

Obesity, which increases influenza disease severity, also extends by about 1.5 days how long influenza A virus is shed from infected adults compared to non-obese adults, according to a multi-year study of two cohorts of Nicaraguan households.

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

Read more Medical News

› Verified 4 days ago

Psychiatry & Neurology in Bala Cynwyd, PA